Biotech — India Patent Cases
108 decisions indexed
Page 3 of 4 · 108 total
Monsnto Technology Llc v.The Assistant Controller of Patents and Designs, Patent Office, Chennai
Monsnto Technology Llc appealed the Patent Controller's order rejecting its patent application for 'Chloroplast Transit Peptides'. The appellant argued that the rejection was based on incomplete consideration of claims and citation of subsequent prior art. The Madras High Court allowed the appeal, set aside the impugned order, and remanded the matter for fresh consideration.
Imclone LLC v.Assistant Controller of Patents and Designs, Government of India
Imclone LLC appealed the rejection of its patent application for an antibody targeting PDGFR alpha, which was rejected under Section 3(c) as being a naturally existing substance. The appellant argued that the antibody was generated through complex hybridoma and transgenic mouse technology, making it recombinant and non-naturally occurring. The High Court set aside the rejection order, finding that the claimed invention was not excluded from patent protection.
Genmab A/S v.Assistant Controller of Patents and Designs, Government of India
Genmab A/S appealed the rejection of its patent application (No. 4718/CHENP/2007) for a monoclonal antibody targeting human CD38. The respondent argued that the antibody was merely a discovery of a naturally existing molecule, thus ineligible under Section 3(c). The High Court set aside the rejection, finding that the antibody was produced through substantial human intervention and possessed inventive step.
Immunas Pharma, Inc. v.Assistant Controller of Patents and Designs, Government of India
Immunas Pharma appealed the rejection of its Indian Patent Application (No.5542/CHENP/2010), which was rejected primarily on grounds that the claimed 6E4 antibody was an inherent feature and not patent-eligible under Section 3(c) as it was discovered in nature. The High Court set aside the rejection, holding that the specific method of production made the antibody patentable.
The Regents Of The University Of California v.Controller General Of Patents, Designs & Trademarks & Anr.
The Regents of the University of California appealed a rejection order issued by the Controller General of Patents regarding their patent application for 'Blockade of Inflammatory Proteases with Theta Defensins'. The rejection primarily hinged on objections related to novelty and inventive step, compounded by concerns over the permissibility of claim amendments under Section 59(1) of the Patents Act. The Delhi High Court ultimately ruled in favor of the appellant, holding that the amendments served only as explanations or incorporated facts already disclosed, thereby allowing the application to be remanded for fresh examination.
Arthrogen Gmbh v.Controller General Of Patents, Designs And Trademarks and Anr
Arthrogen Gmbh appealed the rejection of its Indian patent application for a method involving gold particle enrichment of blood serum. The Patent Office had rejected the claim under Section 3(i) and 3(j) of the Patents Act, arguing it constituted a 'method of treatment.' Arthrogen successfully argued that the claims were directed towards a novel 'method of producing' a substance, not a direct method of treating humans. Consequently, the Delhi High Court set aside the rejection order and remanded the matter for fresh consideration.
Epitech S.P.A. v.The Controller Of Patents
Epitech S.P.A. appealed a rejection order issued by The Controller of Patents, which had denied the grant of its PCT national phase application (No. 6850/DELNP/2014). The Controller's initial decision was based on the finding that the data provided by the Appellant related to an irrelevant compound (PEA-OXA) instead of the claimed subject matter (PEA-OXLE). However, the Delhi High Court found this reasoning insufficient and factually incorrect, noting that the data did indeed include examples pertaining to PEA-OXLE. Consequently, the appeal was allowed, setting aside the Impugned Order and directing the Controller to decide the application afresh.
Onco Therapy Science, Inc. v.Assistant Controller of Patents and Designs, Government of India
Onco Therapy Science appealed the Assistant Controller's decision to reject its application for a patent covering novel peptides used as vaccines against cancers. The appellant argued that the Controller failed to consider their written submissions and supporting materials when issuing the rejection order. The High Court allowed the appeal, remanding the matter back for fresh consideration.
Colgate-Palmolive Company v.Assistant Controller Of Patents And Designs
Colgate-Palmolive Company appealed the refusal of its national phase patent application (4411/DELNP/2007) for 'An Oral Composition'. The refusal was based on lack of inventive step and non-patentability under Section 3(d). However, due to the Appellant's failure to appear despite repeated notices, the court dismissed the appeal for non-prosecution.
University Of Guelph v.Controller Of Patents And Designs
The University of Guelph filed an appeal challenging the Assistant Controller's order dated July 26, 2019, which refused to grant Indian patent application no. 642/DELNP/2011. The refusal was based on lack of inventive step and statutory exclusions under the Patents Act, 1970.
Helix Biomedix Inc. v.Assistant Controller of Patents and Designs, Government of India
Helix Biomedix Inc. appealed the rejection of its patent application for 'Short Bio-Active Peptides for Cellular and Immunological Modulation'. The rejection was based on Section 3(c) because the claimed peptides were derived from Hyalophora cecropia (Cecropia moth). The High Court set aside the order, finding that the respondent failed to address the appellant's submissions regarding the chemical synthesis of the peptides.
Abbvie Biotherapeutics Inc & Abbvie Inc v.Assistant Controller Of Patents Designs
Abbvie Biotherapeutics Inc & Abbvie Inc filed a fresh appeal under Section 117A of the Patents Act, 1970, challenging the order dated July 31, 2023, passed by the Assistant Controller of Patents & Designs refusing to grant patent application no. '201817047767'. The subject matter is related to ANTI-cMet Antibody Drug Conjugates.
Icahn School Of Medicine at Mount Sinai v.Assistant Controller of Patents and Designs, Government of India
The appellant challenged the rejection of its patent application (No.3414/CHENP/2008) for a chimeric NDV vaccine targeting two viruses, specifically Newcastle disease virus and influenza virus. The court reviewed the original rejection based on obviousness and allowed the application to proceed to grant after accepting the amended claims submitted by the appellant.
M/s.Biodelivery Sciences International, Inc. v.M/s.Deputy Controller of Patents and Designs, Government of India, Patent Office
M/s.Biodelivery Sciences International, Inc. filed a Transfer Civil Miscellaneous Appeal (Patents) challenging an earlier order from the Deputy Controller of Patents and Designs. The appellant subsequently instructed their counsel to withdraw the appeal.
Arcturus Therapeutics Inc v.Assistant Controller Of Patents And Designs
Arcturus Therapeutics Inc filed an appeal challenging the Assistant Controller's order refusing to grant a patent (IN'205) for 'Ionizable Cationic Lipid for RNA Delivery'. The refusal was based on non-submission of required data and pending claims.
The Board of Trustees of the Leland Stanford Junior University v.Assistant Controller of Patents and Designs
The appellants challenged the rejection of their patent application (No. 9445/CHENP/2013) by the Controller, which cited objections regarding insufficient disclosure and lack of clarity in the claims. The High Court held that the impugned order lacked the necessary specificity to enable the applicant to address the objections effectively.
New York University v.The Assistant Controller of Patents and Designs
New York University appealed the Assistant Controller's order rejecting its patent application (No. 9210/CHENP/2011) for an invention related to targeting pathological tau proteins. The High Court found that the rejection lacked cogent reasons, particularly regarding amendments and inventive step, and consequently set aside the impugned order.
The Chinese University of Hong Kong v.The Assistant Controller of Patents & Designs, The Patent Office
The Chinese University of Hong Kong appealed the rejection of its patent application (IN 4863), which was refused by the Assistant Controller. The core dispute centered on whether the claimed in vitro method, used to measure sequence imbalance in biological samples from pregnant women, qualified as a non-patentable diagnostic method under Section 3(i) of the Patents Act.
The Chinese University Of Hong Kong Knowledge Transfer Office v.The Assistant Controller of Patents & Designs, The Patent Office
The Chinese University of Hong Kong appealed the rejection of its patent application (IN 4812/CHENP/2012), which was rejected on the grounds that the claimed invention—a process for fetal genomic analysis from maternal samples—was an unpatentable diagnostic method under Section 3(i) of the Patents Act, 1970. The High Court allowed the appeal, holding that determining foetal fraction is related to diagnosis but is not 'diagnostic' in the statutory sense, allowing the patent application to proceed to grant.
Cryomass Llc v.Assistant Controller Of Patents And Designs
Cryomass LLC filed an appeal challenging the rejection of its patent application, '201917048279,' titled "Cryogenic Separation of Plant Material." The initial rejection by the Assistant Controller was based on a lack of inventive steps and falling under Section 3(f) of the Patents Act. Cryomass argued that their non-aqueous cryogenic system offered novel advantages not disclosed in prior art. The Delhi High Court, while setting aside procedural objections regarding delay subject to costs, directed further pleadings before listing the case for final hearing.
Cryomass Llc v.Assistant Controller Of Patents And Designs
Cryomass LLC filed an appeal challenging the Assistant Controller's order dated May 31, 2021, which refused Patent Application No. 201917048279 titled "Cryogenic Separation of Plant Material". The refusal was based on non-fulfillment of requirements under Section 2(1)(ja) and claims falling within Section 3(f) of the Patents Act, 1970.
Commonwealth Scientific and Industrial Research Organization v.The Assistant Controller of Patents and Designs, The Patent Office
The appellant challenged an order rejecting its patent application (No. 2072/CHENP/2011) because the current set of amended claims were deemed beyond the scope of Section 59 of the Patents Act, 1970. The court examined whether the amendments expanded or narrowed the original claim scope and found that the specificity incorporated in the amended claims curtailed rather than expanded the original scope.
Novozymes v.Assistant Controller of Patents & Designs, Patent Office Chennai
Novozymes appealed the refusal by the Assistant Controller of Patents & Designs to grant a patent for its phytase variants. The rejection was based on Sections 3(d) and 3(e) of the Patents Act, 1970. The High Court set aside the rejection concerning claims 1-7, allowing the application to proceed towards grant.
Uab Research Foundation And Anr v.Controller General Of Patents And Designs
The Uab Research Foundation appealed against an order issued by the Assistant Controller of Patents and Designs. The impugned order refused to grant a patent application titled 'Purine Nucleoside Phosphorylase as Enzymatic Activator of Nucleoside Prodrugs' because the claims were deemed to fall within the scope of Section 3(i) of the Act.
Helion Biotech ApS v.Assistant Controller of Patents and Designs, Government of India
Helion Biotech ApS appealed a rejection order by the Assistant Controller of Patents and Designs, which denied grant of a patent for antibodies to MASP-2. The appeal was filed seeking consideration of further amended claims. The High Court set aside the impugned order and remanded the matter back for examination of the amended claims.
Novozymes A/S v.The Assistant Controller of Patents and Designs, Patent Office
Novozymes A/S filed a Transfer Civil Miscellaneous Appeal (Patents) seeking to grant a patent for Indian Patent Application No.1691/CHENP/2010. However, the learned counsel for the appellant subsequently instructed the court to withdraw the appeal.
Akebia Therapeutics Inc. v.Controller General Of Patents, Design, Trademark And Geographical Indications
Akebia Therapeutics Inc. challenged the procedures followed by the Controller General regarding a post-grant opposition filed against its granted patent (IN 287720) for HIF-1α prolyl hydroxylase inhibitor compounds. The Delhi High Court found that the Opposition Board's recommendations were unsustainable due to procedural irregularities in how evidence was presented and processed. Consequently, the court quashed the previous findings, allowed Akebia to lead additional evidence, and remanded the matter back to the Opposition Board for a fresh decision de novo.
Amgen Inc v.The Registrar of Trademarks
Amgen Inc filed a Civil Miscellaneous Appeal challenging the Registrar of Trademarks' refusal to register the mark 'SILIQ' in Class 5. The appeal sought to set aside the previous order and allow the trademark registration to proceed. However, before the court could rule on the merits of the case, Amgen Inc submitted a memo requesting the withdrawal of the appeal. Consequently, the Madras High Court dismissed the appeal as withdrawn.
Agensys Inc v.Assistant Controller Of Patents Asnd Designs
Agensys Inc appealed an order from the Assistant Controller of Patents and Designs which rejected its application under Section 3(d) of the Patents Act, 1970. The appellant argued that their monoclonal antibody invention demonstrated a technical effect (improved affinity/cross-reactivity) not considered by the Controller, thus warranting the setting aside of the impugned order.
Immunovative Therapies Ltd. v.The Controller Of Patents
Immunovative Therapies Ltd. appealed a rejection order dated December 4, 2018, concerning its patent application for 'TH1 VACCINATION PRIMING FOR ACTIVE IMMUNOTHERAPY'. The appellant argued that the rejection based on Section 3(d) and (i) was incorrect, as the invention relates to therapeutic vaccine methods using allogeneic CD3/CD28 cross-linked Thl memory cells.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.